CERO THERAPEUTICS HOLDINGS I (CERO) Stock News
NASDAQ:CERO - Nasdaq - US71902K3032 - Common Stock - Currency: USD
CERO Latest News, Press Relases and Analysis
Top movers in Monday's after hours session
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Which stocks are experiencing notable movement on Wednesday?
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an...
Here are the top movers in Wednesday's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Which stocks are gapping on Wednesday?
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Wondering what's happening in today's pre-market session?
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session.
Top movers in Tuesday's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Which stocks are gapping on Tuesday?
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.
Get insights into the top gainers and losers of Tuesday's pre-market session.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative...
Cero Therapeutics announces 1-for-20 reverse stock split
CERo Therapeutics (CERO) announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company’s common stock, par value $0.0001 per share. The reverse stock split will take effect at 12:01 a.m. Eastern Time on June 13, 2025, and the Company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on June 13, 2025. The CUSIP number of 71902K402 will be assigned to the Company’s Common Stock
Mentions: AAPL
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative...
Bitcoin Miner IREN to Raise $450M From Convertible Debt Offering
The firm plans on using the proceeds to offset potential equity dilution and market risk.
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy...
Palladyne AI to join Russell 3000, Russell 2000 Index
Palladyne AI (PDYN) announced that it has been added as a member of the broad-market Russell 3000 Index, effective after the U.S. market opens on June 30, 2025, as part of the 2025 Russell indexes reconstitution. “We are extremely proud to be included in the Russell 3000 and 2000 Indexes this year,” said Ben Wolff, President and CEO, Palladyne AI. “This is an important achievement for Palladyne AI as we expand our business and aim to impact a bigger investor pool, particularly reaching instituti
Cero announces two granted U.S. patents, European patent application allowance
CERo Therapeutics (CERO) Holdings announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office, and one European patent application has been allowed by the European Patent Office, all of which significantly expand the Company’s intellectual property portfolio. The USPTO granted U.S. Patent No. 12,291,557, titled, “CHIMERIC TIM4 RECEPTORS AND USES THEREOF” on May 6, 2025. The granted claims cover certain design aspects of CER-1236, the Comp
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 ...
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed...